Therapy Modifications in Response to Poorly Controlled Hypertension, Dyslipidemia, and Diabetes Mellitus

Session aims to consider the reasons for measuring therapy modifications and the virtues of measuring outcomes vs. process measures (such as therapy intensification) as indicators of quality of care. Session discusses (1) what "optimal" levels of therapy intensification might be and possible reasons for not intensifying therapy; (2) the use of intermediate outcomes (e.g., proportions of patients in control) and process measures (e.g., proportions of patients screened, therapy modifications); and (3) physician preferences for such types of quality indicators.